



Substitute for form 1449A-B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Complete if Known	
Application Number	10/549,506
Filing Date	July 7, 2006
First Named Inventor	Kim Vilbour Andersen
Group Art Unit	1653
Examiner Name	Not yet assigned
Attorney Docket Number	0272us310

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appeal
	1	5,093,317	Lewis et al.	03-03-1992	
	2	5,258,288	Wydro et al.	11-02-1993	
	3	5,504,064	Morrisey et al.	04-02-1996	
	4	5,516,640	Watanabe et al.	05-14-1996	
	5	5,788,965	Berkner et al.	08-04-1998	
	6	5,817,788	Berkner et al.	10-06-1998	
	7	5,824,639	Berkner	10-20-1998	
	8	5,833,982	Berkner et al.	11-20-1998	
	9	5,837,843	Smirnov et al.	11-17-1998	
	10	5,847,085	Esmon et al.	12-08-1998	
	11	6,100,061	Reiter et al.	08-08-2000	
	12	6,423,826	Nelsestuen et al.	07-23-2002	
	13	6,475,725	Reiter et al.	11-05-2002	
	14	6,693,075	Nelsestuen	02-17-2004	
	15	6,747,003	Nelsestuen	06-08-2004	
	16	6,762,286	Nelsestuen	07-13-2004	
	17	6,806,063	Pedersen et al.	10-19-2004	
	18	6,903,069	Pingel et al.	09-26-2002	
	19	7,026,524	Persson et al.	04-11-2006	
	20	US2003/0100506	Nelsestuen	05-29-2003	
	21	Pending claims of US2003/0100506	Nelsestuen	05-29-2003	
	22	US2003/0100740	Persson et al.	05-29-2003	
	23	US2003/0104978	Persson et al.	06-05-2003	
	24	US2003/0211094	Nelsestuen	11-13-2003	
	25	US2003/0211460	Nelsestuen	11-13-2003	
	26	Pending claims of USSN 10/031,005,	Nelsestuen	Parent application published as	

Examiner Signature	/Samuel Liu/	Date Considered	07/13/2009
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

Complete if Known	
Application Number	10/549,506
Filing Date	July 7, 2006
First Named Inventor	Kim Vilbour Andersen
Group Art Unit	1653
Examiner Name	Not yet assigned
Attorney Docket Number	0272us310

	which is a national phase appn of WO 00/66753, which was cited on previously filed IDS(1449)			WO 00/66753	
--	--	--	--	-------------	--

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number				
	27	WO	02/03075	University of Minnesota	01-10-2002		
	28	WO	02/02764	University of Minnesota	01-10-2002		
	29	WO	02/29025	Novo Nordisk A/S	04-11-2002		
	30	EP	0 296 413	A2	Hoechst Japan	12-28-1988	
	31	EP	0 354 504	A2	Hoechst Japan	02-12-1990	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers, publisher, city and/or country where published.	
	32	Amlijots et al., "Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa," <i>J. Vasc. Surg.</i> , 1997, 25(2):341-346	
	33	Bauer, "Treatment of factor VII deficiency with recombinant factor VIIa," <i>Haemostasis</i> , 1996, 26 (Suppl. 1):155-158	
	34	Broze et al., "Monoclonal anti-human factor VII antibodies. Detection in plasma of a second protein antigenically and genetically related to factor VII," <i>J. Clin. Invest.</i> , 1985, 76:937-946	
	35	Choudhri et al., "Targeted Inhibition of Intrinsic Coagulation Limits Cerebral Injury in Stroke without Increasing Intracerebral Hemorrhage," <i>J. Exp. Med.</i> , 1999, 190:91-99	
	36	Christiansen et al., "Hydrophobic Amino Acid Residues of Human Anticoagulation Protein C that Contribute to its Functional Binding to Phospholipid Vesicles," <i>Biochemistry</i> , 1995, 34:10376-10382	
	37	Dackiw et al., "Prevention of endotoxin-induced mortality by antitissue factor immunization," <i>Arch. Surg.</i> , 1996, 131:1273-1278	
	38	Dahlgren, "Inherited Thrombophilia: Resistance to Activated Protein C as a Pathogenic Factor of Venous Thromboembolism," <i>Blood</i> , 1995, 85:607-614	
	39	Database EMBL, "Coagulation factor VII (EC 3.4.21.21)(Serum prothrombin conversion accelerator)," "Bovine Factor VII. Its purification and complete amino acid sequence," ID FA7_BOVIN, August 1, 1991 (3 pages)	
	40	"Docking of Tissue Factor and Factor VIIa Initiates Blood Coagulation," at http://www.sdsu.edu/IOTW/week46.96/ (1996)	
	41	Esmon et al., "Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C," <i>J. Biol. Chem.</i> , 1982, 257:859-864	

Examiner Signature	/Samuel Liu/	Date Considered	07/13/2009
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

Complete if Known	
Application Number	10/549,505
Filing Date	July 7, 2006
First Named Inventor	Kim Vilbour Andersen
Group Art Unit	1653
Examiner Name	Not yet assigned
Attorney Docket Number	0272us310

42	Evans, Jr. and Nelsestuen, "Importance of cis-Proline 22 in the Membrane-Binding Conformation of Bovine Prothrombin," <i>Biochemistry</i> , 1996, 35:8210-8215
43	Evans and Nelsestuen, "Importance of Cis-Proline 22 and the Aromatic Stack (Residues 41-45) for Prothrombin-Membrane Binding," <i>Protein Sci.</i> , 1996, 5(Suppl. 1):163, Abstract #605-S
44	Felgner et al., "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure," <i>Proc. Natl. Acad. Sci. USA</i> , 1987, 84:7413-7417
45	Fiore et al., "The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa," <i>J. Biol. Chem.</i> , 1994, 269:143-149
46	Freedman et al., "Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX," <i>J. Biol. Chem.</i> , 1996, 271(27):16227-16236
47	Furie and Furie, "The molecular basis of blood coagulation," <i>Cell</i> , 1988, 53:505-518
48	Gao et al., "Protein Tolerance to random amino acid change," <i>Proc. Natl. Acad. Sci.</i> 101(25):9205-9210 (2004)
49	Han et al., "Isolation of a protein Z-dependent plasma protease inhibitor," <i>Proc. Natl. Acad. Sci. USA</i> , 1998, 95:9250-9255
50	He et al., "Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein S-defining modules important for the species specificity of the activated protein C cofactor activity," <i>Eur. J. Biochem.</i> , 1995, 227:433-440
51	Hedner et al., "Recombinant Activated Factor VII in the Treatment of Bleeding Episodes in Patients with Inherited and Acquired Bleeding Disorders," <i>Transfus. Med. Rev.</i> , 1993, 7:78-83
52	Hoppe et al., "Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure. Characterization of Size Distribution, Trapped Volume and Ability to Maintain a Membrane Potential," <i>Biochem. Biophys. Acta</i> , 1985, 812:55-65
53	Hoskins et al., "Cloning and characterization of human liver cDNA encoding a protein S precursor," <i>Proc. Natl. Acad. Sci. USA</i> , 1987, 84:349-353
54	Huang, "Studies on Phosphatidylcholine Vesicles. Formation and Physical Characteristics," <i>Biochemistry</i> , 1969, 8:344-352
55	Humphries et al., "Chemical methods of protein synthesis and modification," <i>Curr. Opin. Biotechnol.</i> , 1991, 2(4):539-543
56	Jurlander et al., "Recombinant Activated Factor VII (rFVIIa): Characterization, Manufacturing, and Clinical Development," <i>Semin. Thromb. Hemost.</i> , 2001, 27(4):373-383
57	Leff, "Genetically Stripped-Down Factor VIII Corrects Bleeding Disorder in Hemophilic Mice," <i>BioWorld Today</i> , 1997, 8(209):1,6
58	Lu and Nelsestuen, "Dynamic Features of Prothrombin Interaction with Phospholipid Vesicles of Different Size and Composition: Implications for Protein - Membrane Contact," <i>Biochemistry</i> , 1996, 35:8193-8200
59	Lu and Nelsestuen, "The prothrombinase reaction: "mechanism switching" between Michaelis-Menten and non-Michaelis-Menten behaviors," <i>Biochemistry</i> , 1998, 35:8201-8209
60	Martinez et al., "Underdecarboxylation of Vitamin K-Dependent Proteins: Occasionally Severe, Possibly Universal." Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics, May 27-31, 2001, Chicago, Illinois, 2 pgs.
61	Matsubara et al., "A receptor tyrosine kinase, Sky, and its ligand Gas 6 are expressed in gonads and support primordial germ cell growth or survival in culture," <i>Dev. Biol.</i> , 1996, 180:499-510
62	Mayer et al., "Prothrombin Association with Phospholipid Monolayers," <i>Biochemistry</i> , 1983, 22(2):316-321
63	Mayer, "Ultra-early hemostatic therapy for intracerebral hemorrhage," <i>Stroke</i> 2003, 34:224-229
64	McDonald et al., "Comparison of Naturally Occurring Vitamin K-dependent Proteins: Correlation of

Examiner Signature	/Samuel Liu/	Date Considered	07/13/2009
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

Complete if Known	
Application Number	10/549,506
Filing Date	July 7, 2006
First Named Inventor	Kim Vilbour Andersen
Group Art Unit	1653
Examiner Name	Not yet assigned
Attorney Docket Number	0272us310

	Amino Acid Sequences and Membrane Binding Properties Suggests a Membrane Contact Site," Biochemistry, 1997, 36:5120-5127	
65	McDonald et al., "Ionic Properties of Membrane Association by Vitamin K-Dependent Proteins: The Case for Univalency," Biochemistry, 1997, 36(50):15589-15598	
66	Morrissey et al., "Quantitation of Activated Factor VII Levels in Plasma Using a Tissue Factor Mutant Selectively Deficient in Promoting Factor VII Activation," Blood, 1993, 81(3):734-744	
67	Muir et al., "The chemical synthesis of proteins," Curr. Opin. Biotechnol., 1993, 4(4):420-427	
68	Nakagaki et al., "Initiation of the Extrinsic Pathway of Blood Coagulation: Evidence for the Tissue Factor-Dependent Autoactivation of Human Coagulation Factor VII," Biochemistry, 1991, 30:10819-10824	
69	Nelsetuen et al., "Membrane association with multiple calcium ions: vitamin-K-dependent proteins, annexins and pentraxins," Current Opinion in Structural Biology 9:433-437 (1999)	
70	Nelsetuen, "Enhancement of Vitamin-K-Dependent Protein Function by Modification of the gamma-Carboxyglutamic Acid Domain: Studies of Protein C and Factor VII," Trends Cardiovasc. Med. 9(6):162-167 (1999)	
71	Nelsetuen et al., "Vitamin K-Dependent Proteins," in 58 VITAMINS AND HORMONES: ADVANCES IN RESEARCH AND APPLICATIONS (Gerald Liwack ed., Academic Press, 2000), pp. 355-389	
72	Nelsetuen et al., "Equilibria Involved in Prothrombin- and Blood Clotting Factor X-Membrane Binding," Biochemistry, 1977, 16(19):4164-4171	
73	Nelsetuen and Sutte, "Properties of Asialo and Glycoprothrombin," Biochem. Biophys. Res. Commun., 1971, 45:198-203	
74	Nicolaeas et al., "A prothrombinase-based assay for detection of resistance to activated protein C," Thromb. Haemost., 1996, 76:404-410	
75	Nicolaeas et al., "Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use," Thromb. Haemost., 1998, 76:200-204	
76	Okaufuji et al., EMBL Data Library, Accession No. S18994, Sept. 10, 1999 (protein C activated precursor, sequence) (Score Search)	
77	Perera et al., "Trans-cis Isomerization of Proline 22 in Bovine Prothrombin Fragment 1: A Surprising Result of Structural Characterization," Biochemistry, 1998, 37:10920-10927	
78	Petersen et al., "Quenching of the amidolytic activity of one-chain tissue-type plasminogen activator by mutation of lysine-416," Biochemistry, 1990, 29:3451-3457	
79	Petrovan et al., "Residue Met ⁷⁶ contributes to the labile enzyme conformation of coagulation factor VIIa," J. Biol. Chem. 2001, 276(9):6616-6620	
80	Ratcliffe et al., "The Importance of Specific γ-Carboxyglutamic Acid Residues in Prothrombin," J. Biol. Chem., 1993, 268(32):24339-24345	
81	Resnick and Nelsetuen, "Prothrombin-Membrane Interaction. Effects of Ionic Strength, pH, and Temperature," Biochemistry, 1980, 19(13):3028-3033	
82	Rezaie and Esmon, "The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives," J. Biol. Chem., 1992, 267:26104-26109	
83	Sakai et al., "The γ-Carboxyglutamic Acid Domain of Human Factor VIIa is Essential for Its Interaction with Cell Surface Tissue Factor," J. Biol. Chem., 1990, 265(4):1890-1894	
84	Schmidel et al., "Organization of the Human Protein S Genes," J. Biol. Chem., 1990, 265(24):7845-7852	
85	Schulman et al., "Feasibility of using recombinant factor VIIa in continuous infusion," Thromb. Haemost., 1996, 75(3):432-436	
86	Schwaible et al., "Protein Structural Requirements and Properties of Membrane Binding by γ-Carboxyglutamic Acid-containing Plasma Proteins and Peptides," J. Biol. Chem., 1989, 264:20288-	

Examiner Signature	/Samuel Liu/	Date Considered	07/13/2009
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

Complete if Known	
Application Number	10/549,506
Filing Date	July 7, 2006
First Named Inventor	Kim Vilbour Andersen
Group Art Unit	1653
Examiner Name	Not yet assigned
Attorney Docket Number	0272us310

20296	
87	Seffernick et al., "Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different," <i>J. Bacteriol.</i> 183(8):2405-2410 (2001)
88	Seshadri et al., "Differences in the Metal Ion Structure between Sr- and Ca-Prothrombin Fragment 1," <i>Biochemistry</i> , 1994, 33:1087-1092
89	Shen et al., "Enhancing the Activity of Protein C by Mutagenesis to Improve the Membrane-Binding Site: Studies Related to Proline 10," <i>Biochemistry</i> , 1997, 36(51):16025-16031
90	Shen et al., "Enhancement of Human Protein C Function by Site-directed Mutagenesis of the γ -Carboxyglutamic Acid Domain," <i>J. Biol. Chem.</i> , 1998, 273(47):31086-31091
91	Smirnov et al., "A Chimeric Protein C Containing the Prothrombin Gia Domain Exhibits Increased Anticoagulant Activity and Altered Phospholipid Specificity," <i>J. Biol. Chem.</i> , 1998, 273(15):9031-9040
92	Thariath et al., "Highly conserved residue arginine-15 is required for the Ca^{2+} -dependent properties of the γ -carboxyglutamic acid domain of human anticoagulation Protein C and activated Protein C," <i>Biochem. J.</i> , 1997, 322:309-315
93	Thim et al., "Amino Acid Sequence and Posttranslational Modification of Human Factor VIIa from Plasma and Transfected Baby Hamster Kidney Cells," <i>Biochemistry</i> , 1988, 27:7785-7793
94	Thomsen et al., "Pharmacokinetics of recombinant factor VIIa in the rat – a comparison of bio-, immuno- and isotope assays," <i>Thromb. Haemost.</i> , 1993, 70(3):458-464
95	Vallette et al., "Construction of mutant and chimeric genes using the polymerase chain reaction," <i>Nucleic Acids Res.</i> , 1989, 17(2):723-733
96	Vrana et al., "Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family," <i>Cancer Res.</i> , 56:5063-5070 (1996)
97	Weber et al., "Modifications of Bovine Prothrombin Fragment 1 in the Presence and Absence of Ca^{2+} Ions," <i>J. Biol. Chem.</i> , 1992, 267(7):4564-4569
98	Wei et al., "Kinetic and Mechanistic Analysis of Prothrombin-Membrane Binding by Stopped-Flow Light Scattering," <i>Biochemistry</i> , 1982, 21:1949-1959
99	Wells, "Additivity of Mutational Effects in Proteins," <i>Biochem.</i> 29(17):8509-8517 (1990)
100	Welsch et al., "Chemical Modification of Prothrombin Fragment 1: Documentation of Sequential, Two-Stage Loss of Protein Function," <i>Biochemistry</i> , 1988, 27:4933-4938
101	Welsch and Neilesstuen, "Amino-terminal alanine functions in a calcium-specific process essential for membrane binding by prothrombin fragment 1," <i>Biochemistry</i> , 1988, 27:4939-4945
102	Yan et al., "Characterization and Novel Purification of Recombinant Human Protein C from Three Mammalian Cell Lines," <i>Bio/Technology</i> , 1990, 8:655-661
103	Zhang et al., "Role of Individual γ -Carboxyglutamic Acid Residues of Activated Human Protein C in Defining Its In Vitro Anticoagulant Activity," <i>Blood</i> , 1992, 80(4):942-952
104	Zwaal et al., "Lipid-protein interactions in blood coagulation," <i>Biochimica et Biophysica Acta</i> , 1998, 1376:433-453

Examiner Signature	/Samuel Liu/	Date Considered	07/13/2009
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.